Literature DB >> 10982601

Resection of hilar cholangiocarcinoma--a European and United States experience.

P F Saldinger1, L H Blumgart.   

Abstract

Improvements in preoperative imaging, patient selection, and refined operative techniques have allowed a more radical surgical approach to hilar cholangiocarcinoma. A total of 269 patients with histologically proven cholangiocarcinoma were treated during a 20-year period under the direction of one surgeon (LHB) over three separate time periods in different institutions: 131 patients at the Hepatobiliary Unit of Hammersmith Hospital, London, England, from January 1977 to September 1985; 48 patients at Inselspital, University of Bern, Switzerland, between October 1986 and October 1990; and 90 patients at Memorial Sloan-Kettering Cancer Center, New York, between March 1991 and April 1997. An increase in the use of concomitant hepatectomy was noted over these time periods, paralleled by an increase in achieving negative margins and in survival. Hilar cholangiocarcinoma should not be considered an incurable disease, but patients should be aggressively evaluated for possible curative resection before any intervention is performed. Good long-term results can be achieved and cure is possible provided a complete tumor resection with negative margins is obtained.

Entities:  

Mesh:

Year:  2000        PMID: 10982601     DOI: 10.1007/s005340050163

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  11 in total

1.  Addition of hepatectomy decreases liver recurrence and leads to long survival in hilar cholangiocarcinoma.

Authors:  Zheng Shi; Ming-Zhi Yang; Qing-Liang He; Rong-Wen Ou; You-Ting Chen
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

2.  Role of caudate lobectomy in type III A and III B hilar cholangiocarcinoma: a 15-year experience in a tertiary institution.

Authors:  Alfred Wei-Chieh Kow; Choi Dong Wook; Sun Choon Song; Woo Seok Kim; Min Jung Kim; Hyo Jun Park; Jin Soek Heo; Seong Ho Choi
Journal:  World J Surg       Date:  2012-05       Impact factor: 3.352

3.  Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma.

Authors:  Daniel A Anaya; Dan G Blazer; Eddie K Abdalla
Journal:  Semin Intervent Radiol       Date:  2008-06       Impact factor: 1.513

4.  Actual long-term outcome of extrahepatic bile duct cancer after surgical resection.

Authors:  Jin-Young Jang; Sun-Whe Kim; Do Joong Park; Young Joon Ahn; Yoo-Seok Yoon; Min Gew Choi; Kyung-Suk Suh; Kuhn Uk Lee; Yong-Hyun Park
Journal:  Ann Surg       Date:  2005-01       Impact factor: 12.969

5.  Improved survival following right trisectionectomy with caudate lobectomy without operative mortality: surgical treatment for hilar cholangiocarcinoma.

Authors:  Kwang Yeol Paik; Dong Wook Choi; Jun Chul Chung; Kyung Tae Kang; Sang Bum Kim
Journal:  J Gastrointest Surg       Date:  2008-03-11       Impact factor: 3.452

Review 6.  Cholangiocarcinoma: a compact review of the literature.

Authors:  Yucel Ustundag; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

7.  Local surgical resection of hilar cholangiocarcinoma: is there still a place?

Authors:  L Capussotti; L Vigano; A Ferrero; A Muratore
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

8.  Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: results of a prospective study.

Authors:  Satoshi Kondo; Satoshi Hirano; Yoshiyasu Ambo; Eiichi Tanaka; Shunichi Okushiba; Toshiaki Morikawa; Hiroyuki Katoh
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

Review 9.  The Landmark Series: Hilar Cholangiocarcinoma.

Authors:  Kevin C Soares; William R Jarnagin
Journal:  Ann Surg Oncol       Date:  2021-04-07       Impact factor: 4.339

Review 10.  Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology.

Authors:  Enrico Gringeri; Martina Gambato; Gonzalo Sapisochin; Tommy Ivanics; Erica Nicola Lynch; Claudia Mescoli; Patrizia Burra; Umberto Cillo; Francesco Paolo Russo
Journal:  J Clin Med       Date:  2020-05-05       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.